Walleye Capital
AIMT

Walleye Capital’s Aimmune Therapeutics AIMT Stock Holding History

Walleye Capital’s Portfolio AIMT Stock Details AIMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-3,200
Closed -$67K – 2440
2019
Q3 		$67K Sell
3,200
-9,900
-76% -$202K ﹤0.01% 1532
2019
Q2 		$273K Buy
+13,100
New +$270K 0.03% 781

Walleye Capital's AIMT Position: Q4 2020 in Review

Walleye Capital sold out of Aimmune Therapeutics (AIMT) in Q4 2020, closing a stake of 68,293 shares — an estimated $2.35M sold.

Walleye Capital first reported a position in AIMT in Q3 2020 and held it in 1 quarter. The position peaked at $2.35M in Q3 2020. 0 funds tracked by Wall St. Rank hold AIMT as of Q4 2020.

  • Walleye Capital reported no remaining Aimmune Therapeutics position as of Q4 2020 after selling out during the quarter.
  • Walleye Capital sold 68,293 Aimmune Therapeutics shares in Q4 2020, an estimated $2.35M.
  • Walleye Capital first reported a position in Aimmune Therapeutics in Q3 2020 and held it in 1 quarter.
  • Walleye Capital's Aimmune Therapeutics position peaked at $2.35M in Q3 2020.
  • 0 funds tracked by Wall St. Rank held Aimmune Therapeutics as of Q4 2020.

Based on Walleye Capital's 13F filing for Q4 2020, filed 16 Feb 2021.